Helping patients manage substance use disorder: Tobacco, alcohol, and other drugs
Substance use disorder (SUD) is a chronic, relapsing, treatable medical condition

Repeated use of substances, whether prescribed, legal, or illegal, can cause neurochemical changes in the brain that often require treatment to overcome.¹

DSM-5 criteria for substance use disorders

SUD is problematic substance (tobacco, alcohol, and/or drug such as an opioid) use that leads to clinically significant impairment or distress.

<table>
<thead>
<tr>
<th>SUD is marked by at least two of these criteria over the past 12 months:²</th>
</tr>
</thead>
<tbody>
<tr>
<td>❑ Use at higher doses or longer than intended or prescribed</td>
</tr>
<tr>
<td>❑ Unsuccessful attempts to control or reduce use</td>
</tr>
<tr>
<td>❑ Significant time lost obtaining, consuming, or recovering from use</td>
</tr>
<tr>
<td>❑ Craving for the substance</td>
</tr>
<tr>
<td>❑ Failure to fulfill obligations because of substance use</td>
</tr>
<tr>
<td>❑ Use causes persistent social or interpersonal problems</td>
</tr>
<tr>
<td>❑ Use displaces social, work, or recreational activities</td>
</tr>
<tr>
<td>❑ Use creates hazardous situations (e.g., while driving)</td>
</tr>
<tr>
<td>❑ Use continues despite physical or psychological problems caused or worsened by the substance</td>
</tr>
<tr>
<td>❑ Tolerance: a reduced effect of the substance despite increasing dosages (in patients taking the substance other than as prescribed)</td>
</tr>
<tr>
<td>❑ Withdrawal (in patients taking the substance other than as prescribed)</td>
</tr>
</tbody>
</table>

The severity of SUD is defined by the number of criteria that are present:

- **Mild SUD**
  - 2-3 criteria

- **Moderate SUD**
  - 4-5 criteria

- **Severe SUD**
  - ≥6 criteria

SUDs can be managed with effective treatments.
SUDs are common, though underrecognized

Figure 1. Results from the 2018 National Survey on Drug Use and Health for adults age 18 and over identified substance use is common, but treatment is not.\textsuperscript{3,4}

Each month many people 18 and older use alcohol, but not all use is problematic.\textsuperscript{3,4}

<table>
<thead>
<tr>
<th>Drug Type</th>
<th>Any use</th>
<th>Diagnosed SUD</th>
<th>Treated SUD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobacco</td>
<td>71.1M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>14.4M</td>
<td>2.3M</td>
<td>7.4M</td>
</tr>
<tr>
<td>Illicit drug use*</td>
<td>49.0M</td>
<td>2.0M</td>
<td></td>
</tr>
</tbody>
</table>

Illicit drug use,* by type, 2018 National Survey on Drug Use and Health\textsuperscript{3,4}

- Marijuana: 40.4M
- Misuse of psychotherapeutics (e.g., stimulants, sedatives): 15.7M
- Opioids: 9.6M
- Stimulants (methamphetamine, cocaine): 7.2M
- Other drugs**: 7.4M

*Drug use numbers do not sum to annual total as multi-substance use is reported.
**Other drugs: heroin, hallucinogens, and inhalants.
Encourage treatment engagement

Nearly 2 million Americans have opioid use disorder (OUD).\textsuperscript{5,6}

Even though medical treatment greatly improves outcomes, only about one in five people with OUD receives it.\textsuperscript{7}

Engaging and retaining patients in medication-based treatment can help to successfully manage SUD, improve quit rates, and reduce the risk of harm and death.\textsuperscript{8-11}

Create a supportive and compassionate dialog with patients in substance use discussions.

- **Ask open-ended questions** to elicit conversation about substance use. e.g., “How do you feel about (substance)?”

- **Include statements of appreciation and understanding.** e.g., “It’s hard to talk about…. I really appreciate your keeping on with this.”

- **Reflect back what the patient has communicated** regarding substance use. This helps the patient know you understand what they are saying. e.g., “I hear that you would like to cut down on your substance use at parties.”

- **Summarize the discussion.**
Identify patients with SUD (tobacco, alcohol, drugs of abuse)

Figure 2. Begin with SBIRT (Screening, Brief Intervention, and Referral to Treatment)\(^3\,12\)

**Screening**

- **Ask** all adult patients about tobacco, alcohol, and drug misuse at least annually, using automated SBIRT-OK screening tablet. If positive, follow with standardized screening tool:
  - AUDIT for alcohol use
  - DAST for drug use
- **Assess** for SUD in patients who screen positive.

**Initiate a Brief Intervention**

- **Advise** the patient about your concern and recommendations raised by the SBIRT-OK screening.
- **Assist** with setting goals and strategies for care.
  - Use motivational interviewing to elicit “change talk.”
  - Encourage safer behavior.
  - Engage the patient in effective treatment.
- **Arrange** follow-up and support from practice.

**Refer to or initiate Treatment for those with SUD**

- Psychosocial support
- Medication assisted treatment
- Behavioral health counseling
- Intensive outpatient or residential treatment

Follow-up and monitor.
Helping patients manage substance use disorder

TOBACCO

Treat tobacco use with medications
Create a plan for patients who are ready to quit.

Select pharmacologic support based on patient preference, cost, and relevant medical and/or psychiatric conditions.

Table 1: Pharmacologic options include:

<table>
<thead>
<tr>
<th>Mechanism of action</th>
<th>nicotine replacement therapy (NRT)</th>
<th>varenicline (Chantix)</th>
<th>bupropion (Wellbutrin, Zyban)</th>
</tr>
</thead>
<tbody>
<tr>
<td>full agonist of nicotine system</td>
<td>partial agonist selective for α4β2 nicotinic acetylcholine receptor subtypes</td>
<td>partial agonist of 5-HT1A receptors</td>
<td></td>
</tr>
<tr>
<td>When to start</td>
<td>anytime</td>
<td>2 weeks before quit date</td>
<td>2 weeks before quit date</td>
</tr>
<tr>
<td>Who can treat</td>
<td>no prescription</td>
<td>any prescriber</td>
<td>any prescriber</td>
</tr>
<tr>
<td>Patient characteristics</td>
<td>anyone</td>
<td>caution: seizures, CVD, serious psych conditions</td>
<td>not if taking monoamine oxidase (MAO) inhibitors, seizures, renal disease</td>
</tr>
<tr>
<td>Dosage forms</td>
<td>patch, spray, gum, lozenge, inhaler</td>
<td>tablet</td>
<td>tablet</td>
</tr>
</tbody>
</table>

Each of these three options alone increase quit rates at one year. Nicotine replacement therapy may be combined with either bupropion or varenicline.

Provide or refer for behavioral support. Even brief, simple advice increases the likelihood of a smoker quitting. More intensive advice may result in higher rates of quitting.\(^{13}\)

All drugs can be effective, though multiple attempts may be needed.\(^{14}\)

Encourage patients to call 1-800-QUIT-NOW (1-800-784-8669) or text QUIT to 47848 to receive text message support.
Treat alcohol use disorder (AUD) with medications and support groups

- Acamprosate and disulfiram had greater durations of abstinence vs. placebo.\textsuperscript{10}
- Acamprosate and naltrexone have similar effects on alcohol consumption.\textsuperscript{15}
- Naltrexone reduces drinking, especially binge drinking, compared to placebo.\textsuperscript{15}

Table 2. Medications for the treatment of AUD\textsuperscript{16}

<table>
<thead>
<tr>
<th>Mechanism of action</th>
<th>acamprosate (Campral)</th>
<th>naltrexone (Revia, Vivitrol)</th>
<th>disulfiram (Antabuse)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>partial agonist GABA/glutamate system</td>
<td>antagonist at opioid receptor</td>
<td>enzyme inhibition leads to build up of toxic acetaldehyde with ethanol ingestion</td>
</tr>
<tr>
<td>When to start</td>
<td>abstinent prior to starting</td>
<td>7-10 days abstinent prior to starting</td>
<td>abstinent prior to starting</td>
</tr>
<tr>
<td>Who can treat</td>
<td>any prescriber</td>
<td>any prescriber</td>
<td>any prescriber</td>
</tr>
<tr>
<td>Patient characteristics</td>
<td>not if suicidal thoughts, renal disease</td>
<td>frequent relapse, cravings, overlapping OUD</td>
<td>frequent relapse</td>
</tr>
<tr>
<td>SUD severity</td>
<td>moderate to severe</td>
<td>moderate</td>
<td>moderate to severe</td>
</tr>
<tr>
<td>Initiating treatment</td>
<td>home</td>
<td>in office for injection, home for tablet</td>
<td>home</td>
</tr>
<tr>
<td>Dosage forms</td>
<td>tablet</td>
<td>tablet or long-acting injection</td>
<td>tablet</td>
</tr>
<tr>
<td>Frequency</td>
<td>three times daily</td>
<td>daily for oral; monthly for injection</td>
<td>daily</td>
</tr>
</tbody>
</table>

Psychosocial treatment increases the likelihood of abstinence after one year of treatment 14-fold more than the general population.\textsuperscript{10}

Peer-support groups like Alcoholics Anonymous are established options to encourage and support remission and recovery.
Medications for opioid use disorder (OUD) are proven to be effective

**Methadone, buprenorphine, and naltrexone can all:**

- Reduce the risk of death\textsuperscript{9,17}
- Improve retention in addiction treatment programs\textsuperscript{18}
- Reduce cravings\textsuperscript{20}

- Decrease opioid misuse\textsuperscript{18-20}
  - Reduce urine samples that test positive for opioids
  - Increase time abstaining from opioids\textsuperscript{19}

**Figure 3. In a randomized trial, buprenorphine lowered the risk of death, improved retention in treatment, and reduced illicit opioid use compared to detoxification and counseling alone.**\textsuperscript{8}

**Medication-based treatment is more effective than detoxification and abstinence-based therapy alone.**\textsuperscript{21}

- Medication-based treatment is so effective for opioid use disorder that it should be offered whether or not behavioral interventions are available.\textsuperscript{22}
- The choice of treatment should be a shared decision between the clinician and the patient; the setting of treatment is an important consideration as well.\textsuperscript{23}
Match the patient with medication treatment for OUD

Table 3. Medications available to treat OUD

<table>
<thead>
<tr>
<th></th>
<th>buprenorphine* (Suboxone, Bunavail, Zubsolv)</th>
<th>methadone</th>
<th>naltrexone (Vivitrol)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of action</strong></td>
<td>partial agonist</td>
<td>full agonist</td>
<td>antagonist</td>
</tr>
<tr>
<td><strong>When to start</strong></td>
<td>must have mild to moderate withdrawal symptoms</td>
<td>anytime</td>
<td>7-10 days abstinent prior to starting</td>
</tr>
<tr>
<td><strong>Who can treat</strong></td>
<td>anyone with a DEA-X waiver**</td>
<td>certified opioid treatment program</td>
<td>any prescriber</td>
</tr>
<tr>
<td><strong>Treatment delivery</strong></td>
<td>no daily clinic visits required</td>
<td>daily clinic visits, administer with supervision</td>
<td>monthly injection</td>
</tr>
<tr>
<td><strong>Patient characteristics</strong></td>
<td>most prefer as first-line treatment</td>
<td>unsuccessful prior treatments; need daily support</td>
<td>mild OUD or those who cannot use agonist</td>
</tr>
<tr>
<td><strong>SUD severity</strong></td>
<td>moderate to severe</td>
<td>moderate to severe</td>
<td>mild OUD</td>
</tr>
<tr>
<td><strong>Initiating treatment</strong></td>
<td>home or in office</td>
<td>certified opioid treatment program</td>
<td>in office for injection</td>
</tr>
<tr>
<td><strong>Dosage forms</strong></td>
<td>sublingual film, tablet, buccal film, long-acting injection or implant</td>
<td>liquid</td>
<td>long-acting injection</td>
</tr>
</tbody>
</table>

*Buprenorphine is often combined with naloxone (e.g., Suboxone) to discourage IV injection. The naloxone precipitates withdrawal if the substance is injected.

**Anyone licensed to prescribe opioids (e.g., M.D., D.O., N.P., P.A.) can complete the training and receive an X-waiver to prescribe buprenorphine.
Promote recovery

1. Recommend or prescribe naloxone (e.g., Narcan) to prevent a potentially fatal overdose.\(^{24}\)

2. Use “person-first” language to reduce stigma.

<table>
<thead>
<tr>
<th>X Language to avoid</th>
<th>✓ Recommended language</th>
</tr>
</thead>
<tbody>
<tr>
<td>addict, abuser, user, junkie</td>
<td>a person with OUD</td>
</tr>
<tr>
<td>clean/dirty urine</td>
<td>urine that is positive/negative for opioids or other substances</td>
</tr>
<tr>
<td>treatment failure</td>
<td>return to use, recurrence, relapse</td>
</tr>
</tbody>
</table>

3. Support patients who return to using the substance.
   - All substance use disorders may take several attempts to achieve sustained remission.
   - SUD is a chronic condition, and these patients will need ongoing support as they work toward recovery.

4. Continue medications for SUD as needed.
   - Patients may require medications to treat SUD for several years, and for OUD possibly indefinitely.\(^{23}\)
   - Patients who taper buprenorphine quickly may be more likely to return to use.\(^{25}\)

Prescribing a medication to treat SUD can build on the trust and relationship a primary care clinician has already established with the patient.

- Tobacco is the most common use disorder for which clinicians use medication treatment.
- Alcohol is the next most common SUD. Using medications combined with psychotherapy, peer-support, and referral for treatment is part of primary care practice.
- Opioid Use Disorder is common and can occur in any practice that has patients treated with opioids for chronic pain.
  - Prescribing buprenorphine or naltrexone can help address these concerns and make care less stressful for both the patient and clinician.
Key points

- Substance use disorders are common. Treatment can help improve patient outcomes.
- Use SBIRT-OK to identify patients who may benefit from treatment.
- Discuss medication and behavioral health treatment options, working with the patient to select the best option.
- Foster a supportive relationship through person-first language and continued encouragement even if patients return to substance use.

REFERENCES:


(3) Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services; 2018.

(4) Substance Abuse and Mental Health Services Administration. Reports and detailed tables from the 2018 National Survey on Drug Use and Health (NSDUH). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.


Partnering organizations

**ODMHSAS**
The Oklahoma Department of Mental Health and Substance Abuse Services (ODMHSAS) promotes healthy communities and access to the highest quality care to enhance the well-being of all Oklahomans. The department is responsible for comprehensive planning and implementation of prevention, treatment, and recovery services for individuals affected by mental illness or substance use disorders.

**SBIRT**
ODMHSAS coordinates Screening, Brief Intervention, and Referral to Treatment (SBIRT OK)—an evidence-based public health approach that aims to identify, reduce, and prevent symptoms of depression and problematic substance use. This integrated approach focuses on identifying risk and intervening with patients in the healthcare setting to prevent the onset of more costly disease and addiction.

**James W. Mold**
located in the Oklahoma Clinical and Translational Science Institute at The University of Oklahoma Health Sciences Center, the Oklahoma Primary Healthcare Improvement Cooperative (OPHC) is the academic research arm of a community-engaged system with a mission to facilitate the diffusion of research innovations into community clinical delivery systems. OPHC partners include our state's County Health Improvement Organizations and other entities critical for translational research in community settings.

**Alosa Health**
This material was produced by Alosa Health, a nonprofit organization that produces educational content and manages and provides consulting for clinical outreach education initiatives. Alosa Health is not affiliated with any pharmaceutical company. For more information, visit AlosaHealth.org.